7月21日 - ** 制药公司Agios Pharmaceuticals AGIO.O 的股价在盘前交易中下跌14.03%，至34.44美元
** 该公司表示，由于中期试验未能显示其用于治疗镰状细胞病的实验性药物tebapivat相较于同类疗法具有显著优势，因此将停止该药物的研发
** 公司表示，该药物虽表现出“与该类药物一致”的活性，但未能确立足以证明进一步开发必要性的差异化优势
** 镰状细胞病是一种遗传性血液疾病，会导致红细胞变形，从而阻碍血流，引发贫血、剧烈疼痛和器官损伤
** 据称，在三种不同剂量的特巴匹伐治疗组中，血红蛋白反应率介于29.4%至47.1%之间，而安慰剂组为33.3%
** 截至上一交易日收盘，AGIO今年以来累计上涨47.2%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.